Penthrox, a methoxyflurane inhaler, has been approved in Canada for short-term relief of moderate to severe pain resulting from trauma or medical procedures, Medical Developments International (MDI) said. The company announced in June 2017 that its marketing authorization application had been accepted for review by Health Canada.
Purdue Pharma, acquired Canadian rights to Penthrox in 2016. MDI CEO John Sharman commented, ” We’re proud to have a partner, like Purdue, with a long and successful legacy in treating pain, now making Penthrox available to Canadian patients who are suffering from moderate to severe acute pain due to trauma or undergoing interventional medical procedures.”
Mr Sharman continued, “Under the terms of the exclusive agreement between the companies, Purdue Pharma (Canada) has the exclusive right to register, market, promote, distribute and sell Penthrox in Canada. MDI will retain clinical development activities, as well as the manufacture and supply of Penthrox to Purdue Pharma (Canada).”
Purdue Pharma Canada VP, R&D, Tom Koutsavlis said, “From my experience, a non-invasive, fast-acting, treatment option that does not require opioid-associated monitoring, like Penthrox, is necessary. Penthrox has the added benefit of being a lightweight, portable, handheld inhaler which is also patient-controlled. Not only has it been shown to be safe and effective, it can also help simplify trauma treatments for both patients and their caregivers.”
In the past few weeks, Penthrox has also received marketing authorization in Germany, Sweden, Norway, Poland, and Croatia.
Read the MDI press release on the Canadian approval.
Read the MDI press release on the German approval.
Read the MDI press release on the approvals in other European countries.
